A comparison of the costs of ceftazidime therapy and gentamicin combinations in three UK hospitals

Malek, Mo; Lynch, William J.; Wells, Nicole; Elliott, T.; Bint, A. J.; Sanderson, P.J.; Jäderberg, Magnus; Davey, Peter

doi:10.1093/jac/29.2.207

Cited by 18 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients receiving intravenous aminoglycosides and glycopeptides undergo serum concentration monitoring ( [17], and T. Elliott, Queen Elizabeth Hospital, Birmingham, personal communication, 1995), which cost £17.30 per assay at 1992/1993 prices [17]. The annual cost of therapeutic drug monitoring for these agents was calculated to be £352,800.…”

Section: Prescribed Drugsmentioning

confidence: 99%

Community-acquired pneumonia: the annual cost to the National Health Service in the UK

Guest¹,

Morris²

1997

Eur Respir J

216

140

View full text Add to dashboard Cite

The aim of this study was to estimate the direct annual healthcare costs to the UK National Health Service (NHS) of managing community-acquired pneumonia.Using a prevalence-based burden of illness approach, health service resource use and corresponding costs attributable to the management of community-acquired pneumonia during 1992/1993 in the UK were obtained from published sources and commercial databases, and supplemented by a telephone survey of general practitioners, finance directors, community nurses, receptionists and nurses in out-patient respiratory clinics, ambulance services, and consultant respiratory physicians. The study was appraised by a Peer Review Panel, representing a cross-section of experts from different locations. This study was a predefined subgroup analysis of a previous, larger study that estimated the annual cost to the NHS of treating all community-acquired lower respiratory tract infections.The analysis shows that there are 261,000 episodes of community-acquired pneumonia annually in the UK, costing £440.7 million at 1992/1993 prices (32% of the annual cost for all community-acquired lower respiratory tract infections). Approximately 83,153 annual cases of community-acquired pneumonia are treated in hospital (32% of all episodes) and account for 96% of the annual cost. The average cost for managing pneumonia in the community is £100 per episode, compared to £1,700-£5,100 when the patient is hospitalized, depending on the length of hospitalization. Hospitalization accounts for 87% of the total annual cost.In conclusion, community-acquired pneumonia in the UK incurs a direct healthcare cost of £440.7 million annually at 1992/1993 prices. Developing and implementing strategies to prevent and minimize hospitalization will significantly reduce this annual cost and should be assessed in future studies.

show abstract

Section: Prescribed Drugsmentioning

confidence: 99%

Community-acquired pneumonia: the annual cost to the National Health Service in the UK

Guest¹,

Morris²

1997

Eur Respir J

216

140

View full text Add to dashboard Cite

show abstract

“…Patients were advised to communicate with one of the Infectious diseases wards or to ask the receptionist to connect a call to doctor for Infectious diseases. The Infectious diseases unit is maintained a 24/7 on-call service with no cross-cover (Malek 1992).…”

Section: Intravenous Treatment At Homementioning

confidence: 99%

Outpatient Intravenous Antibiotic Therapy: Reduces economic burden of patients

Altaf¹,

Zl²,

Nagavamsidhar³

et al. 2018

PharmaTutor

View full text Add to dashboard Cite

OPAT it is a frequent source of questions and formal infectious diseases consultations. OPAT is always less expensive than inpatient therapy. Financial savings have been found with OPAT when compared with in hospital stays. The use of intravenous (IV) antibiotics for the treatment of serious infections has become common around the world. It is accepted as the standard treatment for many infectious diseases including other chronic infection like sepsis, meningitis, endocarditis etc. The goals of OPAT program are to provide expert care to patients on IV antibiotics, manage side effects and infections, reduces the need for hospital readmissions. The OPAT having a series of program patient care team includes doctors, nurses, and clinical and hospital pharmacists who are skilled in management of infectious diseases. Intravenous therapy outside the hospital, has only recently become possible, with the introduction of new Antibiotics, better catheters for vascular access, and improved infusion devices. Health care professionals have pioneered the development of OPAT and worked together to develop safe and effective programs. The antibiotics used for OPAT care are chosen for safety, effectiveness and ease of administration and money saving. The IV delivery system needed in the home is much simpler than the large, complicated IV pumps you see in the hospital. OPAT allows suitable patients on intravenous (IV) antibiotics to be discharged early from hospital and treated in their home or community setting by a team of specialist nurses.

show abstract

“…23 Time and motion studies often are used to determine the labor and material costs associated with the treatments. 24,25 The costs are calculated by multiplying the pharmacist's or nurse's wage rate by the preparation or administration time needed for each dose plus the costs of any materials needed to prepare or administer the treatment. Although this approach may be an improvement on the studies that evaluate only level 1 costs, studies that consider level 2 costs have many of the same limitations.…”

Section: What Costs Are Studied?mentioning

confidence: 99%

Pitfalls Associated with Commonly Used Methods for Pharmacoeconomic Analyses

Klepser¹

2002

Pharmacotherapy

View full text Add to dashboard Cite

Demonstrating the economic value of treatment has become an important objective of many clinical trials. Awareness of the limitations of the methods used in pharmacoeconomic studies of infectious diseases will help in understanding why improved methods are needed to adequately describe the costs associated with infectious episodes. Current analyses generally consider three levels of cost and use three methods to determine costs associated with an infectious episode. However, these costs and the methods for obtaining them may not be appropriate in all studies. Future pharmacoeconomic research needs to adhere to established principles but embrace new methodologies to improve the validity and usefulness of these studies.

show abstract

A comparison of the costs of ceftazidime therapy and gentamicin combinations in three UK hospitals

Cited by 18 publications

References 0 publications

Community-acquired pneumonia: the annual cost to the National Health Service in the UK

Community-acquired pneumonia: the annual cost to the National Health Service in the UK

Outpatient Intravenous Antibiotic Therapy: Reduces economic burden of patients

Pitfalls Associated with Commonly Used Methods for Pharmacoeconomic Analyses

Contact Info

Product

Resources

About